Physician profile
Bruce Brent
NPI 1093726879
$17,949.39
in general payments reported to CMS, 2019-2025
29 companies · $283 in 2025
The $283 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $1,213 · 2021: $703 · 2022: $734 · 2023: $210 · 2024: $175 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $668.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $10,513.94 | 2019-2020 | |
| Medtronic, INC. | $1,121.93 | 2021-2025 | Symplicity G3 |
| Medtronic Vascular, INC. | $961.74 | 2019-2020 | |
| Amgen INC. | $728.72 | 2019-2025 | Repatha |
| Philips North America LLC | $533.44 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $521.63 | 2019-2021 | |
| Heartflow, INC. | $472.55 | 2019-2022 | |
| Pfizer INC. | $408.47 | 2019-2021 | |
| Astellas Pharma US INC | $280.90 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.24 | 2019-2020 | |
| Chiesi USA, INC. | $249.06 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $232.29 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $226.04 | 2019-2021 | |
| Abiomed | $187.04 | 2020-2022 | |
| Boston Scientific Corporation | $169.97 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $169.48 | 2019-2020 | |
| Cathworks, INC. | $145.19 | 2019-2020 | |
| Irhythm Technologies, INC. | $131.98 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $112.94 | 2019 | |
| Sanofi-Aventis U.S. LLC | $81.38 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $75.19 | 2019-2020 | |
| Amarin Pharma, INC. | $73.62 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $71.66 | 2019 | |
| Gilead Sciences, INC. | $66.72 | 2019 | |
| Lundbeck LLC | $44.38 | 2019-2020 | |
| Getinge USA Sales, LLC | $38.68 | 2019 | |
| Bardy Diagnostics, INC. | $20.97 | 2022 | |
| Abbott Laboratories | $20.71 | 2019 | |
| Octapharma USA, INC. | $20.53 | 2025 | Fibryga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Brent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.